## Jiri Suttnar

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9243191/publications.pdf

Version: 2024-02-01

62	767	14	25
papers	citations	h-index	g-index
62	62	62	1088
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Fibrinopeptides A and B release in the process of surface fibrin formation. Blood, 2011, 117, 1700-1706.	1.4	76
2	Surface plasmon resonance biosensor for the detection of VEGFR-1â€"a protein marker of myelodysplastic syndromes. Analytical and Bioanalytical Chemistry, 2012, 402, 381-387.	3.7	53
3	Proteome changes in platelets activated by arachidonic acid, collagen, and thrombin. Proteome Science, 2010, 8, 56.	1.7	44
4	Tryptophan Metabolism, Inflammation, and Oxidative Stress in Patients with Neurovascular Disease. Metabolites, 2020, 10, 208.	2.9	43
5	Acquired Dysfibrinogenemia Secondary to Multiple Myeloma. Acta Haematologica, 2008, 120, 75-81.	1.4	34
6	Antioxidants change platelet responses to various stimulating events. Free Radical Biology and Medicine, 2009, 47, 1707-1714.	2.9	33
7	The adhesion of blood platelets on fibrinogen surface: Comparison of two biochemical microplate assays. Platelets, 2006, 17, 470-476.	2.3	32
8	Plasma proteome changes in cardiovascular disease patients: novel isoforms of apolipoprotein A1. Journal of Translational Medicine, 2011, 9, 84.	4.4	30
9	The Effect of Reagents Mimicking Oxidative Stress on Fibrinogen Function. Scientific World Journal, The, 2013, 2013, 1-8.	2.1	26
10	Platelet Adhesion to Fibrinogen, Fibrin Monomer, and Fibrin Protofibrils in Flowing Blood - The Effect of Fibrinogen Immobilization and Fibrin Formation. Thrombosis and Haemostasis, 1997, 78, 1125-1131.	3.4	26
11	Two cases of congenital dysfibrinogenemia associated with thrombosis – Fibrinogen Praha III and Fibrinogen PlzeÅ^. Thrombosis and Haemostasis, 2009, 102, 479-486.	3.4	22
12	Plasma Levels of Aminothiols, Nitrite, Nitrate, and Malondialdehyde in Myelodysplastic Syndromes in the Context of Clinical Outcomes and as a Consequence of Iron Overload. Oxidative Medicine and Cellular Longevity, 2014, 2014, 1-10.	4.0	21
13	Fibrinogen Nov $ ilde{A}^{1}$ /2 Ji $ ilde{A}$ n and Praha II: Cases of hereditary A $\hat{I}$ ± 16 Argâ†'Cys and A $\hat{I}$ ± 16 Argâ†'His dysfibrinogenem Thrombosis Research, 2007, 121, 75-84.	iia. 1.7	20
14	Plasma proteome changes associated with refractory cytopenia with multilineage dysplasia. Proteome Science, 2011, 9, 64.	1.7	18
15	Proteome Changes in the Plasma of Myelodysplastic Syndrome Patients with Refractory Anemia with Excess Blasts Subtype 2. Disease Markers, 2014, 2014, 1-8.	1.3	16
16	Impact of posttranslational modifications on atomistic structure of fibrinogen. PLoS ONE, 2020, 15, e0227543.	2.5	16
17	Two novel fibrinogen variants in the C-terminus of the $\hat{Bl^2}$ -chain: fibrinogen Rokycany and fibrinogen Znojmo. Journal of Thrombosis and Thrombolysis, 2010, 30, 311-318.	2.1	15
18	Plasma proteome changes associated with refractory anemia and refractory anemia with ringed sideroblasts in patients with myelodysplastic syndrome. Proteome Science, 2013, 11, 14.	1.7	15

#	Article	IF	CITATIONS
19	Fibrinopeptide-releasing enzymes in the venom from the southern copperhead snake (Agkistrodon) Tj ETQq1	1 0.784314 rg	gBT/Overlo
20	A novel fibrinogen variant? Praha I: hypofibrinogenemia associated with? Gly351Ser substitution. European Journal of Haematology, 2007, 78, 410-416.	2.2	12
21	Plasma protein alterations in the refractory anemia with excess blasts subtype 1 subgroup of myelodysplastic syndrome. Proteome Science, 2012, 10, 31.	1.7	12
22	Enhanced plasma protein carbonylation in patients with myelodysplastic syndromes. Free Radical Biology and Medicine, 2017, 108, 1-7.	2.9	12
23	A novel fibrinogen variant – Liberec: dysfibrinogenaemia associated with γ Tyr262Cys substitution. European Journal of Haematology, 2008, 81, 123-129.	2.2	11
24	Congenital dysfibrinogenemia A $\hat{l}\pm$ Gly13Glu associated with bleeding during pregnancy. Thrombosis Research, 2011, 127, 277-278.	1.7	11
25	The effect of i‰-3 polyunsaturated fatty acids on the liver lipidome, proteome and bile acid profile: parenteral versus enteral administration. Scientific Reports, 2019, 9, 19097.	3.3	11
26	Fibrinogen Åumperk II: Dysfibrinogenemia in an individual with two coding mutations. American Journal of Hematology, 2012, 87, 555-557.	4.1	10
27	Lipidomic Analysis to Assess Oxidative Stress in Acute Coronary Syndrome and Acute Stroke Patients. Metabolites, 2021, 11, 412.	2.9	10
28	The ω-3 Polyunsaturated Fatty Acids and Oxidative Stress in Long-Term Parenteral Nutrition Dependent Adult Patients: Functional Lipidomics Approach. Nutrients, 2020, 12, 2351.	4.1	9
29	Incorporation of Fibrin, Platelets, and Red Blood Cells into a Coronary Thrombus in Time and Space. Thrombosis and Haemostasis, 2022, 122, 434-444.	3.4	9
30	Effect of Blood Component Coatings of Enosseal Implants on Proliferation and Synthetic Activity of Human Osteoblasts and Cytokine Production of Peripheral Blood Mononuclear Cells. Mediators of Inflammation, 2016, 2016, 1-15.	3.0	8
31	A New Approach for the Diagnosis of Myelodysplastic Syndrome Subtypes Based on Protein Interaction Analysis. Scientific Reports, 2019, 9, 12647.	3.3	8
32	Dysfibrinogenemia in childhood: two cases of congenital dysfibrinogens. Blood Coagulation and Fibrinolysis, 2010, 21, 640-648.	1.0	7
33	A novel natural mutation Al̂ $\pm$ Phe98lle in the fibrinogen coiled-coil affects fibrinogen function. Thrombosis and Haemostasis, 2014, 111, 79-87.	3.4	7
34	Two novel mutations in the fibrinogen $\hat{I}^3$ nodule. Thrombosis Research, 2014, 134, 901-908.	1.7	6
35	On the molecular conformation of human haemopexin. Biochimica Et Biophysica Acta (BBA) - Protein Structure, 1977, 495, 260-267.	1.7	5
36	Simplified platelet sample preparation for <scp>SDS</scp> â€ <scp>PAGE</scp> â€based proteomic studies. Proteomics - Clinical Applications, 2012, 6, 374-381.	1.6	5

#	Article	IF	CITATIONS
37	Staining of proteins for 2D SDSâ€PAGE using Coomassie Blueâ€"speed versus sensitivity?. Electrophoresis, 2013, 34, 1972-1975.	2.4	5
38	No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia. Hematological Oncology, 2014, 32, 87-93.	1.7	5
39	Fibrin Clot Formation under Oxidative Stress Conditions. Antioxidants, 2021, 10, 923.	5.1	5
40	Comparison of rat and human major platelet glycoproteins. Comparative Biochemistry and Physiology Part B: Comparative Biochemistry, 1991, 99, 399-403.	0.2	4
41	Three cases of abnormal fibrinogens: Åumperk (Bβ His67Leu), Uniãov (Bβ Gly414Ser), and Brno (γArg275His). Thrombosis and Haemostasis, 2008, 100, 1199-1200.	3.4	4
42	Novel homozygous fibrinogen AÎ $\pm$ chain truncation causes severe afibrinogenemia with life threatening complications in a two-year-old boy. Thrombosis Research, 2013, 132, 490-492.	1.7	4
43	Distortion of the electrophoretic titration curves of some proteins. Electrophoresis, 1989, 10, 704-708.	2.4	3
44	Production and simple purification of a protein encoded by part of the gag gene of HIV-1 in the Escherichia coli HB101F+ expression system inducible by lactose and isopropyl- $\hat{l}^2$ -d-thiogalactopyranoside. Biomedical Applications, 1994, 656, 127-133.	1.7	3
45	Long-Term Effects on the Lipidome of Acute Coronary Syndrome Patients. Metabolites, 2022, 12, 124.	2.9	3
46	Structural and Functional Characterization of Four Novel Fibrinogen Mutations in FGB Causing Congenital Fibrinogen Disorder. International Journal of Molecular Sciences, 2022, 23, 721.	4.1	3
47	Extension of the Human Fibrinogen Database with Detailed Clinical Information—The αC-Connector Segment. International Journal of Molecular Sciences, 2022, 23, 132.	4.1	3
48	The action of a fibrin-promoting enzyme from the venom of Agkistrodon contortrix contortrix on rat fibrinogen and plasma. Toxicon, 1990, 28, 1364-1367.	1.6	2
49	Characterization of Platelet Antigen for CD45RA Monoclonal Antibodies. Immunobiology, 1995, 192, 272-277.	1.9	2
50	Proteomic analysis of plasma samples from acute coronary syndrome patients â€" The pilot study. International Journal of Cardiology, 2012, 157, 126-128.	1.7	2
51	Enhanced levels of asymmetric dimethylarginine in a serum of middle age patients with myelodysplastic syndrome. Journal of Hematology and Oncology, 2013, 6, 58.	17.0	2
52	Abnormal Fibrinogen ZlÃn (γThr21lle) with Missense Mutation Causing Hypofibrinogenemia. Acta Haematologica, 2014, 132, 140-143.	1.4	2
53	Low Plasma Citrate Levels and Specific Transcriptional Signatures Associated with Quiescence of CD34+ Progenitors Predict Azacitidine Therapy Failure in MDS/AML Patients. Cancers, 2021, 13, 2161.	3.7	2
54	Molecular Dynamic Simulations Suggest That Metabolite-Induced Post-Translational Modifications Alter the Behavior of the Fibrinogen Coiled-Coil Domain. Metabolites, $2021,11,307.$	2.9	2

#	Article	IF	CITATIONS
55	EDMA 2000 as a matrix for high-performance liquid chromatography of human haemoglobin chains. Biomedical Applications, 1994, 656, 119-122.	1.7	1
56	Determination of the Putative Binding Sites for Thrombin Receptor Activating Peptide through a Hydropathic Complementary Approach. Thrombosis and Haemostasis, 2000, 83, 165-170.	3.4	1
57	Proteomic analysis of the plasma samples of patients with stable angina pectoris. Cor Et Vasa, 2012, 54, e22-e26.	0.1	1
58	Hsp70 Trap Assay for Detection of Misfolded Subproteome Related to Myelodysplastic Syndromes. Analytical Chemistry, 2019, 91, 14226-14230.	6.5	1
59	Protein Carbonylation in Patients with Myelodysplastic Syndromes. Blood, 2015, 126, 5232-5232.	1.4	1
60	Three cases of abnormal fibrinogens: sumperk (Bbeta His67Leu), Unicov (Bbeta Gly414Ser), and Brno (gammaArg275His). Thrombosis and Haemostasis, 2008, 100, 1199-200.	3.4	1
61	Surface plasmon resonance analysis of immobilized fibrinogen and fibrin and their interaction with thrombin and fibrinogen., 1999, 3570, 176.		O
62	Thrombosis-associated hypofibrinogenemia. Blood Coagulation and Fibrinolysis, 2022, Publish Ahead of Print, .	1.0	0